Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02500407 · ClinicalTrials.gov registry record · Phase 1
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 713
- Enrollment target
NCT02500407 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 713 participants.
The verdict
NCT02500407, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 713 participants
- Enrollment target
Study Summary
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Interventions
- DRUG Atezolizumab
- DRUG BTCT4465A (Mosunetuzumab) IV
- DRUG BTCT4465A (Mosunetuzumab) SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 713 participants |
| Start Date | 2015-09-15 |
| Est. Completion | 2025-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02500407
The ClinicalTrials.gov registry entry for NCT02500407 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 713 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atezolizumab is the first listed.
NCT02500407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02500407 about?
NCT02500407 is a clinical study titled "A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)". This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will ...
What is the current status of trial NCT02500407?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 713 participants. The study started on 2015-09-15. Estimated completion is 2025-09-01.
What interventions are being tested in trial NCT02500407?
The interventions under investigation include: Atezolizumab (DRUG), BTCT4465A (Mosunetuzumab) IV (DRUG), BTCT4465A (Mosunetuzumab) SC (DRUG).
Who is sponsoring clinical trial NCT02500407?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.